Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › DPP-4 inhibitors

DPP-4 inhibitors

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of DPP-4 inhibitors

3 trials tracked of DPP-4 inhibitors: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 14 citations.

3Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Other / NA 2
  1. Phase 4 Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Completed · 14 cited
  2. N/A Empa PASS on Urinary Tract Malignancies Completed
  3. N/A Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Mini-review links insulin to worse COVID-19 outcomes in type 2 diabetes patients
Nephrology RCT
Mini-review links insulin to worse COVID-19 outcomes in type 2 diabetes patients Diabetes Meds Do Not Stop COVID-19
A mini-review of observational studies in patients with type 2 diabetes mellitus found that insulin was linked to worse COVID-19 outcomes, w…
Recent research proves that common diabetes pills do not protect you from getting sick or dying from a virus infection.
Frontiers Apr 15, 2026
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
Diabetes & Endocrinology
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD Why Ozempic's Heart Benefits May Have Nothing to Do With Weight Loss
An observational study of 47,199 patients with baseline cardiovascular disease in a U.S.
A massive real-world study of over 47,000 heart patients suggests that semaglutide may protect the heart through direct biological effects —…
medRxiv Apr 14, 2026